Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A substantially purified polypeptide comprising:

(a) an amino acid sequence set forth as SEQ ID NO: 14~~, or a variant thereof having a conservative substitution~~; or

(b) an immunogenic ~~fragment~~ polypeptide comprising an immunogenic epitope of eight to ten consecutive amino acids of a polypeptide ~~the protein~~ comprising the amino acid sequence set forth as SEQ ID NO: 14~~, or variant thereof having a conservative substitution~~;

~~(c) a polypeptide with at least 90% sequence identity to the amino acid sequence set forth as SEQ ID NO: 14 that is specifically recognized by an antibody that specifically recognizes the protein comprising the amino acid sequence set forth as SEQ ID NO: 14; or~~

~~(d) a polypeptide that has at least 90% sequence identity with the amino acid set forth as SEQ ID NO: 14 and that, when processed and presented in the context of Major Histocompatibility Complex molecules, activates T lymphocytes against cells that express the protein encoded by the amino acid sequence set forth as SEQ ID NO: 14.~~

Claim 2 (currently amended): The substantially purified polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 14~~, or a variant thereof having a conservative substitution~~.

Claim 3 (currently amended): ~~The~~ A substantially purified polypeptide ~~of claim 1, wherein the polypeptide comprises an immunogenic fragment~~ comprising at least ten consecutive amino acids of the amino acid sequence as set forth as SEQ ID NO: 14~~, or a variant thereof having a conservative substitution~~.

Claim 4 (currently amended): ~~The~~ A substantially purified polypeptide ~~of claim 1, wherein the polypeptide has~~ comprising an amino acid sequence with at least 90% sequence identity to the ~~an~~ amino acid sequence ~~as~~ set forth as SEQ ID NO: 14 wherein the polypeptide is

expressed in prostate cancer cells, breast cancer cells, or both. ~~and is specifically recognized by an antibody that specifically recognizes the amino acid sequence as set forth as SEQ ID NO: 14~~.

Claim 5 (canceled).

Claim 6 (currently amended): A composition comprising ~~a~~ the polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Claims 7-9 (canceled).

Claim 10 (previously presented): A substantially purified recombinant nucleic acid molecule encoding the polypeptide of claim 1.

Claims 11-14 (canceled).

Claim 15 (previously presented): The substantially purified recombinant nucleic acid molecule of claim 10, operably linked to a promoter.

Claim 16 (currently amended): The substantially purified recombinant nucleic acid molecule of claim 15, wherein the nucleotide sequence encodes a polypeptide comprising the amino acid sequence as set forth as SEQ ID NO: 14~~, or a variant thereof having a conservative substitution~~.

Claim 17 (currently amended): The substantially purified recombinant nucleic acid molecule of claim 15, wherein the nucleotide sequence encodes a polypeptide comprising ~~the amino acid sequence of an immunogenic fragment of the protein comprising~~ an immunogenic epitope of eight to ten consecutive amino acids of the amino acid sequence as set forth as SEQ ID NO: 14~~, or variant thereof having a conservative substitution~~.

Claims 18-19 (canceled).

Claim 20 (previously presented): A method for eliciting an immune response in a subject, comprising administering to a subject a composition, comprising:

(a) the polypeptide of claim 1;

(b) a substantially purified nucleic acid encoding the polypeptide of claim 1 in an expression vector;

(c) an antigen presenting cell pulsed with a polypeptide comprising an epitope of the polypeptide of claim 1, or an immunogenic fragment thereof thereby eliciting an immune response in the subject.

Claims 21-23 (canceled).

Claim 24 (previously presented): The method of claim 20 wherein the subject has prostate cancer.

Claim 25 (previously presented): The method of claim 20, wherein the subject has breast cancer.

Claim 26 (previously presented): The method of claim 20, wherein the subject is a female at risk for developing breast cancer.

Claim 27 (currently amended): The method of claim 20 wherein the administered composition further comprises CD8+ cells that are sensitized with antigen presenting cells pulsed with a polypeptide comprising an epitope of the protein having an amino acid sequence as set forth as SEQ ID NO: 14~~or a variant thereof having a conservative substitution~~.

Claim 28 (currently amended): The method of claim 20, further comprising co-administering to the subject an immune adjuvant ~~comprising~~ selected from the group consisting of a non-specific immune adjuvant, a subcellular microbial product and fraction, a hapten, an immunogenic protein, an immunomodulator, an interferon, a thymic hormone, ~~or~~ and a colony stimulating factor.

Claim 29 (currently amended): The method of claim 20, comprising administering an antigen presenting cell pulsed with a polypeptide comprising an epitope of the protein having an amino acid sequence as set forth as SEQ ID NO: 14~~, or a variant thereof having a conservative substitution.~~

Claim 30 (previously presented): The method of claim 20, wherein the substantially purified nucleic acid is in a recombinant virus.

Claim 31 (previously presented): The method of claim 20 wherein the nucleic acid has a sequence as set forth as SEQ ID NO: 13 or a degenerate version thereof.

Claim 32 (previously presented): A method of eliciting an immune response, comprising administering to a subject a composition, comprising a recombinant bacterial cell comprising the nucleic acid molecule of claim 15.

Claim 33 (previously presented): A method of eliciting an immune response, comprising administering to a subject a composition, comprising an autologous recombinant cell comprising the nucleic acid molecule of claim 15.

Claim 34 (currently amended): The method of claim 27 wherein the CD8+ cells are cytotoxic T ~~lymphocytess~~ lymphocytes.

Claim 35 (previously presented): The method of claim 34 wherein the cytotoxic T lymphocytes are tumor infiltrating lymphocytes.

Claim 36 (previously presented): A method for detecting a cancer in a subject, comprising detecting in a sample from the subject the hybridization of a probe specific for a nucleic acid that encodes the polypeptide of claim 1, whereby the hybridization of the probe to the nucleic acid indicates that the subject has cancer.

Claim 37 (original): The method of claim 36, comprising detecting the transcript.

Claim 38 (original): The method of claim 36, comprising detecting the protein.

Claim 39 (original): The method of claim 36, comprising contacting RNA from the cell with a nucleic acid probe that specifically hybridizes to the transcript under hybridization conditions, and detecting hybridization.

Claim 40 (previously presented): The method of claim 36, comprising disrupting the cell and contacting a portion of the cell contents with a chimeric molecule comprising a targeting moiety and a detectable label, wherein the targeting moiety specifically binds to the protein, and detecting the label bound to the protein.

Claim 41 (previously presented): The method of claim 36, wherein the hybridization is detected in a sample comprising a lymph node cell of the subject.

Claim 42 (previously presented): The method of claim 36, wherein the hybridization is detected in a sample comprising a breast biopsy cell of the subject.

Claim 43 (previously presented): An antibody that specifically binds to the polypeptide of claim 1.

Claim 44 (previously presented): A method of modulating levels of a protein comprising the amino acid sequence as set forth as SEQ ID NO: 14 in a cell, comprising introducing into the cell a composition comprising: a ribozyme that specifically cleaves a nucleic acid of claim 10, an antisense oligonucleotide that specifically binds to a nucleic acid of claim 10, a DNA binding protein that binds specifically to a nucleic acid of claim 10, or a nucleic acid of claim 10, operatively linked to a promoter.

Claim 45 (previously presented): The substantially purified polypeptide of claim 1, wherein the polypeptide comprises the amino acid sequence set forth as SEQ ID NO: 14.

Claim 46 (previously presented): The nucleic acid of claim 10, comprising the nucleic acid sequence as set forth as SEQ ID NO: 13.

Claim 47 (previously presented): A vector comprising the nucleic acid of claim 15.

Claim 48 (previously presented): The method of claim 36, comprising detecting the hybridization in a prostate epithelial cell of a male.

Claim 49 (previously presented): The method of claim 36, comprising detecting the hybridization in a breast cell of a female.

Claim 50 (currently amended): A method of detecting cancer in a subject, comprising ~~detecting the~~ contacting a sample from the subject with ~~of~~ an antibody that specifically binds a protein having the amino acid sequence as set forth as SEQ ID NO: 14, ~~or a variant thereof having a conservative substitution in a sample from the subject~~, and

detecting binding of the antibody, whereby ~~detection of the~~ binding of the antibody indicates that the subject has cancer.

Claim 51 (previously presented): The method of claim 36, wherein the subject is a male and the cell is a prostate epithelial cell.

Claim 52 (previously presented): The method of claim 36, wherein the subject is a female and the cell is a breast cell.

Claim 53 (previously presented): The method of claim 51, wherein the sample comprises a lymph node cell.

Claim 54 (previously presented): The method of claim 51, wherein the sample comprises a breast biopsy cell.

Claim 55 (new): The polypeptide of claim 1, wherein the polypeptide comprises amino acids 42 to 57 of SEQ ID NO: 15.

Claim 56 (new): A nucleic acid encoding the polypeptide of claim 4.

Claim 57 (new): The nucleic acid of claim 56, operably linked to a promoter.

Claim 58 (new): A method for eliciting an immune response in a subject, comprising administering to a subject a composition, comprising:

(a) the polypeptide of claim 4;

(b) a substantially purified nucleic acid encoding the polypeptide of claim 4 in an expression vector;

(c) an antigen presenting cell pulsed with a polypeptide comprising an immunogenic epitope of eight to ten consecutive amino acids of the polypeptide of claim 4,

thereof thereby eliciting an immune response in the subject.